UK markets open in 1 hour 5 minutes

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
134.46-0.85 (-0.63%)
At close: 04:00PM EDT
134.46 0.00 (0.00%)
After hours: 05:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close135.31
Open135.44
Bid134.37 x 100
Ask134.74 x 500
Day's range133.12 - 136.07
52-week range85.08 - 161.00
Volume221,750
Avg. volume371,568
Market cap7.722B
Beta (5Y monthly)0.53
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

    COPENHAGEN, Denmark, June 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 8:00 a.m. ET in Miami, Florida. A live webcast of the fireside chat will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website sho

  • GlobeNewswire

    Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

    - 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited confirmed clinical responses with no new safety signals - 45% of efficacy-evaluable patients (5 out of 11) whose disease progressed on check-point inhibitors exhibited confirmed clinical responses when treated with TransCon IL-2 β/γ as monotherapy or in combination treatment COPENHAGEN, Denmark,

  • GlobeNewswire

    Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

    COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency (GHD), hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston. “In addition to physician and caregiver presentations in pediatric GHD,